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Objective. To develop an additive numerical scoring scheme for the Classic BILAG index.
Methods. SLE patients were recruited into this multi-centre cross-sectional study. At every assessment, data were collected on disease
activity and therapy. Logistic regression was used to model an increase in therapy, as an indicator of active disease, by the Classic
BILAG score in eight systems. As both indicate inactivity, scores of D and E were set to 0 and used as the baseline in the fitted model.
The coefficients from the fitted model were used to determine the numerical values for Grades A, B and C. Different scoring schemes were
then compared using receiver operating characteristic (ROC) curves. Validation analysis was performed using assessments from a
single centre.
Results. There were 1510 assessments from 369 SLE patients. The currently used coding scheme (A¼9, B¼3, C¼1 and D/E¼0) did not
fit the data well. The regression model suggested three possible numerical scoring schemes: (i) A¼11, B¼6, C¼1 and D/E¼0; (ii) A¼12,
B¼6, C¼1 and D/E¼0; and (iii) A¼11, B¼7, C¼1 and D/E¼0. These schemes produced comparable ROC curves. Based on this,
A¼12, B¼6, C¼1 and D/E¼0 seemed a reasonable and practical choice. The validation analysis suggested that although the A¼12,
B¼6, C¼1 and D/E¼0 coding is still reasonable, a scheme with slightly less weighting for B, such as A¼12, B¼5, C¼1 and D/E¼0, may
be more appropriate.
Conclusions. A reasonable additive numerical scoring scheme based on treatment decision for the Classic BILAG index is A¼12, B¼5,
C¼1, D¼0 and E¼0.
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Introduction
The Classic BILAG index is a comprehensive composite clinical
index that has been validated for the assessment of SLE disease
activity [1–3]. This index was developed on the principle of the
physician’s intention to treat. It is a transitional index that
captures changing severity of clinical manifestations. It has an
ordinal scale scoring system by design that produces an overview
of disease activity across eight systems. The individual system
scores were not intended to be summated into a global score.
As such, Classic BILAG scores should be treated as ordinal data.
However, the accommodation of ordinal data and the
multiplicity of systems do limit the statistical analyses that can
be performed. In situations where a single summary (numerical)
measure for the Classic BILAG index is desirable, such as when
assessing laboratory data, the coding scheme of A¼9, B¼3,
C¼1 and D/E¼0 is currently used [4]. This scheme was devel-
oped on an ad hoc basis during a period in the early 1990s when
the Classic BILAG index was being compared on both real and
paper patients with two global score indices, the SLEDAI and
the SLAM. It was then felt that a Grade A score (the most
active disease score) should be approximately three times numeri-
cally that of a Grade B score (the second most active score)
(Isenberg DA, personal communication). However, this numerical
coding scheme has not been validated. Over the years, there has
been increasing concern that this is not optimal as it is not con-
sistent with the premise on which the grading of the Classic
BILAG index was defined in terms of the need for treatment.
With the current coding scheme, eight system scores of Grade C
(all systems with mild disease activity) would result in a total
numerical score of 8 which is comparable with a single Grade A
(numerical score of 9) and more than two Grade Bs (numerical
score of 6) numerically. This is conceptually inappropriate as mild
disease activity (Grade C) would not be treated in the same
manner as moderate to severe disease activity (Grades A and B)
with regards to the use of immunosuppressives and/or moderate
to high-dose corticosteroids.
In response to these concerns, this analysis was performed to
develop an additive numerical scoring scheme for the Classic
BILAG index based on treatment decision, utilizing data collected
in routine clinical practice, which would allow the system scores
to be summed into a global numerical score.
Patients and methods
This was a multi-centre cross-sectional study involving eight
centres across the UK in which the primary objective was the
validation of the BILAG-2004 index that has been reported
previously [5]. Patients with SLE who satisfied four or more of
the revised ACR criteria for classification of SLE were recruited
[6, 7]. Patients were excluded from the study if they were pregnant,
<18 years of age or unable to give valid consent. This study
received multi-centre research ethical approval from Hull and
East Riding Research Ethics Committee as well as approval
from the local research ethics committees of all participating
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study was carried out in accordance with the Declaration of
Helsinki.
This study commenced in March 2005 and was completed
in August 2006. At every assessment, data on disease activity
(using SLEDAI 2000, Classic BILAG and BILAG-2004 indices)
and treatment (current treatment and changes to treatment) were
collected. The majority of patients recruited into this study had
more than one assessment during this period. Only the data
for the Classic BILAG index will be discussed in this article.
Classic BILAG index
This is an ordinal scale index with eight systems (general, muco-
cutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory,
vasculitis, renal and haematology) [1, 8]. Each system is assigned
a disease activity grade, ranging from A to E. Grade A represents
very active disease requiring immunosuppressive drugs and/or
prednisolone dose of >20mg daily (or equivalent). Grade B
represents moderate disease activity requiring a lower dose of
corticosteroids, anti-malarials or NSAIDs. Grade C indicates
mild disease requiring symptomatic therapy, whereas Grade D
implies no current disease activity but the system had previously
been affected. Grade E indicates no current or previous disease
activity.
Change in therapy
Change in therapy has previously been chosen as the reference
standard for disease activity in the criterion validity analysis of
the BILAG-2004 index [5]. This is based on the well-defined
benchmark for active disease, which is the decision to treat.
In line with this, change in therapy was regarded as an indicator
of disease activity and used as the response (outcome) variable
in this study.
Change in therapy was the difference in treatment after the
patient was assessed, compared with the therapy that the patient
was on prior to the assessment (or change in treatment following
the assessment) [5]. The medications of interest included immuno-
suppressives, anti-malarials, glucocorticoids, biological therapy,
topical glucocorticoids, topical immunosuppressives, intravenous
immunoglobulins, plasmapheresis, prasterone, thalidomide and
retinoids. NSAIDs were not included as they are commonly
used to treat non-lupus indications (especially for pain relief)
and some could be obtained over the counter as non-prescription
medication. A robust definition for change in therapy was used,
as in our previous study [5]. Three categories of change were
defined, namely ‘no change’, ‘increase in therapy’ or ‘decrease in
therapy’.
Increase in therapy was defined as any increase in the medica-
tions of interest regardless of any concomitant reduction in other
medications. Decrease in therapy was defined as any decrease in
the medications of interest without any concomitant increase in
other medications. However, change in therapy was not just
a simple change in the dose of the medications. The following
special circumstances had to be taken into account as described
previously [5]:
(i) dosing levels based on body weight;
(ii) step-down change of immunosuppressive therapy;
(iii) gradual escalation of immunosuppressive therapy following
initiation;
(iv) increase in immunosuppressive therapy for steroid-sparing
effect; and
(v) reduction or discontinuation of therapy due to side effects.
For some immunosuppressives, different dosing levels based on
body weight were used in the definition of change in therapy
(Table 1). A change in therapy was deemed to have occurred
when there had been a change in the dosing level of these
medications. These levels were based on clinical judgement and
experience. For medications that were not listed in Table 1, a
simple change in dose did constitute a change in therapy.
A switch in immunosuppressive therapy was generally con-
sidered as an increase in therapy except in the situation of
changing cyclophosphamide to AZA, MTX or cyclosporin. This
is because it is a common practice to make such a change once
the disease is under control, as prolonged cyclophosphamide
therapy is associated with significant toxicity (step-down phase).
In fact, this step-down phase would be equivalent to a reduction
in therapy as the discontinuation of cyclophosphamide was
considered as a decrease in therapy, whereas the initiation of the
other immunosuppressive was not considered as an increase in
therapy. In the case of the change from cyclophosphamide to
mycophenolate mofetil, the situation was clarified with the local
investigator as to whether the change was the result of failed
cyclophosphamide (indicating an increase in therapy) or as a
step-down phase (indicating a decrease in therapy).
As most immunosuppressives have potential toxicity, it is
common practice to start at a low dose and gradually escalate
to the target dose. To take this into account, any increase in the
dose of immunosuppressives within the first 3 months of initiation
was considered to be part of an escalation plan to achieve the
target dose and not as an increase in therapy. Similarly, it is
also a common practice to reduce the glucocorticoid dose
gradually during this period, as immunosuppressives will have a
steroid-sparing effect. Therefore, any concomitant reduction
in the glucocorticoid dose during the escalation phase was not
considered as a reduction in therapy.
If an immunosuppressive agent was started only for its steroid-
sparing effect, this was not considered to be an increase in therapy.
If any medication was decreased or discontinued due to side
effects, this was not considered to be a reduction in therapy.
For this analysis, change in therapy was restricted into two
categories, namely ‘increase in therapy’ and ‘no increase in
therapy’. Therefore, ‘no increase in therapy’ represents a com-
bination of ‘no change’ and ‘decrease in therapy’. Increase in
therapy is chosen as the marker for active disease in the analysis,
rather than decrease in therapy, as increase in treatment is very
likely to occur with active disease and is unlikely to occur with
inactive disease. The reverse does not hold true as inactive disease
does not necessarily lead to a decrease in therapy, particularly if
the patient is already on low-dose therapy (such as low-dose
glucocorticoids).
Validation analysis
A validation exercise was performed using assessments from
a single centre (Birmingham) from January 2003 to December
2004. In this centre, data on disease activity (using the Classic
BILAG index) and treatment were collected prospectively at
every assessment. However, the data collection on the treatment
at every assessment is slightly different to that of the sample used
in the primary analysis. As a result, the same definition of change
in therapy could not be applied in the validation sample. Here,
change in therapy was deemed to have occurred when there had
been a change in the dose or change in the immunosuppressive
drugs. There was no allowance for special circumstances such as
dosing levels based on body weights, escalation phase, step-down
TABLE 1. Dosing levels of medications used for definition of change in therapy
Medications Level 1 Level 2 Level 3
AZA, mg/kg/day <1 1–2.4 52.5
Mycophenolate mofetil, g/day <22 3
Cyclosporin A, mg/kg/day <2 2–3 >3
Tacrolimus, mg/kg/day <0.10 0.10–0.15 >0.15
MTX, mg/week <10 10–15 >15
Oral cyclophosphamide, mg/kg/day <1 1–2 >2
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reduction or discontinuation of therapy due to side effects.
Statistical analysis
All statistical analyses were performed using Stata (Stata
Corporation, TX, USA). Logistic regression was used to relate
the probability of an increase in therapy (outcome variable)
to the total number of Grades A, B, C and D/E (explanatory
variables) obtained across the eight systems at each assessment.
Grades D and E were combined together for this analysis as they
both indicate inactivity. Therefore, four categorical scores were
possible (A, B, C and D).
What will be termed as the total counts model corresponds to
the logistic regression model which takes the form of:
logitðPÞ¼ þ AxAþ BxBþ CxCþ DxD ð1Þ
where P is the probability of an increase in therapy;   is
the intercept term; xA, xB, xC and xD are explanatory variables
representing the number of Grades A, B, C and D/E scores,
respectively, at each assessment;  A,  B,  C and  D are the coeffi-
cients for the corresponding explanatory variables xA, xB, xC
and xD.
Grade D/E was used as the reference category in the model
which meant that the coefficient  D for Grade D/E was assigned
the value of 0. Furthermore, as Grade D/E indicated inactivity, it
was decided prior to analysis that both Grades D and E would be
assigned the numerical value of 0. The values of the coefficients
for the other explanatory variables ( A,  B and  C) were estimated
and used to derive the numerical values for Grades A, B and C.
Estimation was based on generalized estimating equations with
an independent working correlation matrix to account for the
correlation between multiple assessments from the same patient.
This generated a robust estimate for the variance matrix of the
maximum likelihood estimates.
The aim is to provide a relative weighting of Grades A, B, C
and D/E that can be used independently of the above logistic
regression model. Therefore, the ratios of the estimates of these
coefficients (denoted by ^  A, ^  B and ^  C) provided the basis for the
formulation of possible numerical values for Grades A, B and C.
For simplicity, the numerical value for Grade C was fixed at 1.
Therefore, the numerical value for Grade A should be close to
^  A/ ^  C, and similarly, the numerical value for Grade B should
approximate ^  B/ ^  C.
The fitting of the total counts model suggested some possible
coding schemes. For each proposed coding scheme, the corre-
sponding numerical global score at each assessment can be calcu-
lated. This is achieved by converting the ordinal score of each
system into its suggested numerical equivalence and summating
the numerical score of the eight systems. Therefore, the numerical
global score is given by the following formula:
Numerical global score ðxSÞ¼ASxAþBSxBþxC
where xA, xB and xC represent the number of Grades A, B and C,
respectively, at each assessment, and AS and BS represent the
numerical values assigned to Grades A and B, respectively, by
the particular coding scheme.
Further logistic regression models were used to determine
how well these proposed coding schemes and the currently
used scheme (A¼9, B¼3, C¼1 and D/E¼0) fit with the total
counts model. These single variable models were in the form of:
logitðpÞ¼ þ SxS ð2Þ
where P is the probability of an increase in therapy;   is the
intercept term; xS is the numerical global score obtained using a
particular coding scheme;  S is the coefficient for the numerical
global score xS.
Wald tests were used to check if there was a demonstrable
difference in fit between a single variable model and the total
counts model. A comparable fit between the single variable
model of a particular coding scheme and the total counts
model would indicate that the coding scheme suggested for
Grades A, B, C and D/E is reasonable.
Receiver operating characteristic (ROC) curves, plots of sensi-
tivity vs 1   specificity, together with the area under these curves
(AUCs) were used to compare the performance (predictive power)
of the different coding schemes [9]. Larger AUC values are
preferable, since the higher the AUC the better the scheme is at
predicting increase in treatment.
For the validation analysis, ROC curves for the developed
coding scheme and the currently used coding scheme were
produced and compared with those for the original (primary
analysis) sample.
Results
There were 369 SLE patients and they contributed 1510 assess-
ments for the analysis. Of the 369 patients, 88.6% had more than
one assessment during the study period. The demographics of
the patients are summarized in Table 2.
Of the 1510 assessments, an increase in therapy was recorded
342 (22.6%) times. Summary of the Classic BILAG index scores
attained at each assessment, depending on whether or not an
increase in therapy was observed, is given in Table 3. There
were eight systems, so the maximum possible occurrence of
a particular grade at each assessment was eight.
TABLE 2. Demographics of patients recruited into the study (n¼369)
Patient characteristics
Female sex, % 92.7
Age, mean  S.D., years 41.6 13.2
Race, %
Caucasian 59.9
Afro-Caribbean 18.4
South Asian 18.4
Oriental 1.4
Others 1.9
Disease duration, mean  S.D., years 8.8 7.7
Number of assessments, %
One 11.4
Two 12.5
Three 19.8
Four 18.7
Five 15.2
Six 10
Seven or more 8.1
TABLE 3. Summary of the Classic BILAG index scores at each assessment, by
change in therapy (n¼1510)
Increase
in therapy
No increase
in therapy
No. of visits with 51 Grade A 76 19
No. of visits with 51 Grade B and 0 Grade A 210 236
No. of visits with 51 Grade C, 0 Grade B and 0 Grade A 53 781
No. of visits with just Grades D or E recorded 3 143
Total 342 1179
Number of Grade A at each visit, mean (range)
a 0.3 (0–4) <0.1 (0–2)
Number of Grade B at each visit, mean (range)
a 1.1 (0–5) 0.3 (0–5)
Number of Grade C at each visit, mean (range)
a 1.8 (0–6) 1.6 (0–6)
Number of Grades D or E at each visit, mean (range)
a 4.9 (1–8) 6.2 (2–8)
aThis is the mean number of Grades A, B, C and D/E at each assessment with a possible
range of 0–8.
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Maximum likelihood estimation of the total counts model gave
the coefficient estimates ^  A ¼ 2:73, ^  B ¼ 1:54 and ^  C ¼ 0:24.
When a baseline score of 1 was assigned to a Grade C score,
the estimated coefficients suggested that the numerical value
for Grade A should be approximately 2.73/0.24¼11.4, and
the numerical value for Grade B should be approximately
1.54/0.24¼6.4. This suggested the following possible coding
schemes:
(i) A¼11, B¼6, C¼1 and D/E¼0;
(ii) A¼12, B¼6, C¼1 and D/E¼0;
(iii) A¼11, B¼7, C¼1 and D/E¼0.
There was significant evidence that a model using the current
coding scheme (A¼9, B¼3, C¼1 and D/E¼0) for the Classic
BILAG index did not fit the observed data as well as the total
counts model (Wald test P<0.001) and that a more appro-
priate coding scheme should be considered. The three new
coding schemes did fit the data as well as the total counts
model, with non-significant (Wald test minimum P¼0.77) differ-
ence between the models using the new coding schemes and
the total counts model. This was also reflected in the AUC
measures, with the AUC for the three proposed schemes being
 0.864 and the AUC for the current coding scheme (A¼9,
B¼3, C¼1 and D/E¼0) being 0.857. To summarize, the results
suggested that any of the three proposed schemes would be a
reasonable choice, and represented an improvement on the current
coding scheme (A¼9, B¼3, C¼1 and D/E¼0). For ease of
interpretability in application, the coding scheme of A¼12,
B¼6, C¼1 and D/E¼0 was considered the preferred scheme.
Validation analysis
There were 405 SLE patients contributing 2360 assessments to the
validation analysis: 93.2% were females, 21% Caucasian, 19%
Asian, 54.3% Afro-Caribbean, 1% Orientals and 12.4% others.
The mean age at first assessment was 42.4 years, with mean
disease duration of 12.4 years.
Of the 2360 assessments, increase in therapy occurred in 439
(18.6%) assessments. When the coding scheme of A¼12, B¼6,
C¼1 and D/E¼0 was applied, the AUC measure for the ROC
curve (0.769) was less, as would be expected, than that for the
original sample from which the coding was derived (0.864).
The application of the two other coding schemes, discussed in
the previous section, resulted in the same difference between
AUC measures.
Interestingly, the currently used coding scheme (A¼9, B¼3,
C¼1 and D/E¼0) also generated a decline in AUC measures
from 0.857 to 0.769, which was identical to that for the newly
proposed coding scheme (Fig. 1). The comparability of the ROC
curves for the two coding schemes using the validation sample
also reflected the fact that, for this sample, a formal improvement
from use of the new coding scheme was not demonstrated.
Further formal analysis was done using a logistic regression
model containing the global numerical score (xS) together with
total counts of Grades A and B (xA and xB). This analysis (data
not shown) revealed that the comparable performance of the
current coding scheme (A¼9, B¼3, C¼1 and D/E¼0) with
the proposed coding scheme (A¼12, B¼6, C¼1 and D/E¼0)
in the validation sample was due to the weight assigned to
Grade B relative to Grade A (9/3¼3 in the current
coding scheme compared with 12/6¼2 in the proposed coding
scheme). This suggested that a coding scheme with a lower relative
weighting of Grade B to A was more appropriate. Hence, a new
coding scheme (A¼12, B¼5, C¼1 and D/E¼0) with a lower
relative weighting of Grade B to A of approximately 2.5 was
considered. This new coding scheme (A¼12, B¼5, C¼1 and
D/E¼0) had comparable performance with the proposed
coding scheme of A¼12, B¼6, C¼1 and D/E¼0 in both the
original or validation samples (Fig. 1).
Discussion
This is the first study that has attempted to determine formally
an additive numerical coding scheme for the Classic BILAG index
using data collected from actual clinical practice. It is clear from
the results that the current coding scheme (A¼9, B¼3, C¼1 and
D/E¼0) for this index is inappropriate, which was not wholly
unexpected. From the regression model (total counts model),
three new coding schemes were found to be reasonable, and repre-
sented an improvement on the currently used coding scheme
(that was not derived empirically and was never validated) [4].
For practical application, the coding scheme of A¼12, B¼6,
C¼1 and D/E¼0 was proposed as the preferred choice.
However, the validation exercise did not detect a formal improve-
ment of the proposed coding scheme (A¼12, B¼6, C¼1 and
D/E¼0) when compared with the current coding scheme (A¼9,
B¼3, C¼1 and D/E¼0). Further formal analysis suggested
a compromise between the currently used coding scheme and
the proposed coding scheme, in terms of the relative weight
of a Grade B to A (for which the optimal value remains unclear),
in the form of A¼12, B¼5, C¼1 and D/E¼0. This new
coding scheme has been shown to be appropriate to both the
original and validation samples. With this new coding scheme,
an assessment with all eight systems scoring Grade C will not
have a numerical score that would be almost equivalent to a
Grade A or greater than that of two Grade Bs which is the case
with the current coding scheme (A¼9, B¼3, C¼1 and D/E¼0).
Therefore, the new coding scheme is intuitively more acceptable
within clinical practice than the current coding scheme.
The proposed coding scheme did not fit the validation data
as well as the original data, which is not unexpected. Notably,
there is a comparable decline in the AUC measures, between the
original sample and validation sample, for both the currently used
and proposed coding schemes. This finding suggests that there
are inherent differences between the samples analysed. It is very
likely that the difference in the definition of change in therapy
between these two samples is a factor. In the validation sample,
the definition of change in therapy did not allow for circumstances
such as dosing levels based on body weights, escalation phase,
step-down phase, increase in therapy only for steroid-sparing
effect, and reduction or discontinuation of therapy due to side
effects. With this difference in definition, we might have expected
a higher proportion of increase in therapy in the validation
sample, but that was not the case (18.6% in the validation
sample and 22.6% in the original sample). Hence, there were
FIG. 1. ROC curves to compare sensitivity and specificity of the different
coding schemes for the original (multi-centre) and validation samples.
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samples. It should be noted that the original data were collected
from a variety of centres, whereas the validation sample was from
a single centre, albeit with a broad ethnic mix. Apart from that,
detailed training on how to use the index was provided to the
physicians involved in the original sample (prior to the start of
the study), which was more formal and extensive than the one
provided to the physicians involved in the validation sample.
This may have resulted in an operational difference in the index
between these two samples. Although the validation sample is
not ideal, it is the best available sample with prospective data
collection (on disease activity and treatment) that is suitable for
the validation analysis.
Change in therapy was used as the reference standard for
disease activity in the absence of a better alternative. To date,
the best benchmark to define active disease is the decision as to
whether the disease activity should be treated. Physician’s global
assessment has been used previously as a gold standard, but this
has been shown to perform unsatisfactorily with poor agreement
between physicians in several studies [10–13].
One of the limitations of this study is in the cross-sectional
design whereby only the disease activity at the time of assessment
is taken into account. This does not take into consideration other
factors that will have an impact on the treatment decision such as
prior disease activity, current therapy, previous therapy (and
its response), presence of comorbidities and patient’s opinion
(in particular, refusal to change therapy as advised). It is not
possible to model all these factors into the analysis of this study.
Furthermore, the reference for disease activity in this study of
‘actual change in therapy’ is different to that of ‘intention to
treat’, which is the premise for the scoring of the Classic
BILAG index. Actual change in therapy involves consideration
of many factors (as discussed above), whereas the main considera-
tion for intention to treat is disease activity. It is recognized
that there is a variation between physicians in their threshold in
changing treatment for a certain level of disease activity.
Therefore, it was not surprising that increase in treatment did
not occur in all assessments with active disease (at least one
Grade A or B) in this study as demonstrated in Table 3.
Another drawback of this study is that the coding scheme is
not derived from data with a full range of possible scores. For
example, there was only one assessment with more than two
Grade As recorded, and only 15 assessments with more than
two Grade Bs recorded along with no Grade A. Thus, the data
are too sparse to investigate the possibility of ceiling effects on the
number of Grade As and Bs that contribute to increase in therapy.
Nevertheless, the dataset is representative of those seen in routine
clinical practice. In our experience, an assessment with three
or more Grade As is a rarity (almost invariably in a very ill
patient) and it would be very difficult to undertake another
larger prospective multi-centre study than the one used for this
analysis.
The key point to note is that the coding scheme of A¼12,
B¼5, C¼1 and D/E¼0 is appropriate for both samples and is
consistent with the principles on which the index is based.
Therefore, in situations where a single summary numerical
measure of the Classic BILAG index is desired, this coding
scheme provides a reasonable way of achieving this. It should
not be assumed that the same numerical coding scheme is
applicable to the BILAG-2004 index. It has to be emphasized
that the Classic BILAG index is ordinal scale with eight system
scores by design, for which we strongly recommend that it should
be treated as such in studies. Any coding scheme resulting in
a single numerical value will not be able to capture all the
information available from this index. Hence, there will be
many circumstances in which the use of a single score will be
inappropriate and the ordinal system scores should be used.
Rheumatology key message
  The unvalidated numerical coding for the Classic BILAG index
(A¼9, B¼3, C¼1, D/E 0) is not appropriate. A12, B5, C1 and
D/E 0, based on data, is more reasonable.
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